Drugmakers’ deal making will plow ahead despite antitrust scrutiny, analysts say By: MarketWatch July 12, 2023 at 15:59 PM EDT Big pharma goes shopping as "patent cliff" puts more than $225 billion in revenues at risk. Read More >> Related Stocks: AbbVie Activision Blizzard, Inc - Common Stock Amgen DICE Therapeutics, Inc. - Common Stock Eli Lilly Horizon Therapeutics Public Limited Company - Ordinary Shares Microsoft Pfizer Seagen Inc. - Common Stock
